Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to trace how FDA milestones, trial costs, and insider sales shape Tarsus Pharmaceuticals (TARS) prospects? Biotech filings run hundreds of pages, packed with clinical jargon about XDEMVY, TP-04, and TP-05. Missing a single risk factor in the annual report could skew your valuation.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries. Whether you need the Tarsus Pharmaceuticals quarterly earnings report 10-Q filing or a quick take on an 8-K announcing pivotal trial results, our platform highlights cash runway, trial endpoints, and revenue clues in plain language. Wondering about Tarsus Pharmaceuticals insider trading Form 4 transactions? Get instant alerts the moment executives buy or sell shares.
Here’s what you can uncover in seconds:
- Tarsus Pharmaceuticals annual report 10-K simplified – find R&D spend, patent timelines, and Demodex market sizing.
- Tarsus Pharmaceuticals Form 4 insider transactions real-time – monitor executive stock moves around FDA approvals.
- Tarsus Pharmaceuticals proxy statement executive compensation – see how milestone payouts align with shareholder value.
- Tarsus Pharmaceuticals 8-K material events explained – track trial readouts and licensing deals without wading through legalese.
Investors use these insights to compare quarter-over-quarter burn rates, gauge pipeline momentum, and spot early red flags. Understanding Tarsus Pharmaceuticals SEC documents with AI means faster, better-informed decisions—no medical dictionary required.
RTW Investments, LP and Roderick Wong report beneficial ownership of 3,424,180 shares of Tarsus Pharmaceuticals common stock, representing 8.1% of the outstanding shares based on 42,014,237 shares outstanding as reported in the companys quarterly report dated April 24, 2025. The shares are held by the RTW Funds, for which RTW Investments is the investment adviser, and Dr. Wong reports the same aggregate holding on behalf of those funds.
The filing shows no sole voting or dispositive power (0 shares) and shared voting and dispositive power over the 3,424,180 shares. The Reporting Persons certify the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported sales of common stock on 08/11/2025 as shown on this Form 4. The filing lists dispositions of 53,635 and 6,000 shares and shows a transaction price of $50 where indicated, with reported beneficial ownership of 818,106 shares following the transactions. The sales were effected automatically under a Rule 10b5-1 trading plan adopted December 12, 2024. Azamian is trustee of the Bobak Azamian Living Trust (established April 16, 2018) and has voting and dispositive power over the trust shares. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Tarsus Pharmaceuticals filed a Form 144 reporting a proposed sale of 6,000 shares of common stock through Merrill Lynch in Newport Beach with an aggregate market value of $300,000. The filing lists 42,214,106 shares outstanding and an approximate sale date of 08/11/2025. The shares were acquired on 01/13/2017 in a private placement from Tarsus Pharmaceuticals and were paid for in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
